The ALPI Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population featuring targeted disruption of the ALPI gene, which encodes intestinal alkaline phosphatase. This polyclonal model eliminates ALPI function while maintaining the heterogeneous editing profiles characteristic of pooled cell populations, offering a robust system for studying loss-of-function phenotypes without clonal selection artifacts.
HEK293T cells are an adherent epithelial cell line derived from human embryonic kidney 293 cells, engineered to stably express the SV40 large T-antigen. This modification supports high-level protein expression and viral production, making HEK293T a preferred host for reconstituting signaling modules. Their rapid proliferation and high transfectability facilitate straightforward exogenous gene delivery, enabling the dissection of intestinal epithelial pathways when paired with relevant receptors and transcription factors.
ALPI encodes a GPI-anchored enzyme that dephosphorylates bacterial lipopolysaccharide (LPS) and other phosphomonoesters. By dephosphorylating LPS, ALPI dampens Toll-like receptor 4 (TLR4) activation and the subsequent MyD88-dependent signaling cascade, reducing NF-??B and I??B?? phosphorylation and suppressing tumor necrosis factor alpha (TNF-??) and interleukin 6 (IL-6) production. ALPI transcription is driven by CDX2 and is positively regulated by butyrate, vitamin D, retinoic acid, and Wnt/??-catenin signaling. ALPI interacts with lipid raft components to localize at the apical membrane, where it functions upstream of TLR4 to constrain inflammatory responses.
Although HEK293T cells do not natively express ALPI, CRISPR-mediated knockout creates a defined genetic absence, enabling clean reconstitution experiments and direct assessment of ALPI-dependent LPS detoxification. This model is instrumental for studying mechanisms of intestinal inflammation relevant to inflammatory bowel disease, necrotizing enterocolitis, and metabolic endotoxemia, providing a platform to dissect how loss of ALPI exacerbates TLR4/NF-??B-driven cytokine release and disrupts gut barrier homeostasis.
Researchers can employ these polyclonal cells in LPS dephosphorylation assays, NF-??B luciferase reporter systems, and small-molecule screening to identify ALPI modulators. Loss of ALPI activity is readily confirmed by alkaline phosphatase activity assays with pNPP, western blotting for ALPI, and RT-qPCR for pro-inflammatory cytokines. These applications establish the cells as a versatile tool for intestinal phosphatase research. For further information, contact Ascent Research.
